Cited by 949Protein Kinase Regulation and GTPase SignalingProtein Degradation and InhibitorsCancer Mechanisms and Therapy

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Drugging the ‘undruggable’ cancer targets

Open access

Dang, Chi V., Reddy, E. Premkumar, Shokat, Kevan M., Soucek, Laura·2017·Nature Reviews Cancer

DOI 10.1038/nrc.2017.36PMC PMC5945194

Open this paper in CoChat — free account

Abstract

The term 'undruggable' was coined to describe proteins that could not be targeted pharmacologically. However, progress is being made to 'drug' many of these targets, and therefore more appropriate terms might be 'difficult to drug' or 'yet to be drugged'. Many desirable targets in cancer fall into this category, including the RAS and MYC oncogenes, and pharmacologically targeting these intractable proteins is now a key challenge in cancer research that requires innovation and the development of new technologies. In this Viewpoint article, we asked four scientists working in this field for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrc.2017.36

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
MYC on the Path to Cancer
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Self-citation
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,160
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Self-citation
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536

Flagged first, then by citations

Show all 57 references

Sorted by citations

Items 601–700 of 949

Design, Synthesis and Evaluation of WD-repeat containing protein 5 (WDR5) degradersPreprint
Dölle, A., Adhikari, B., Krämer, A., Weckesser, J., Berner, N., Berger, L. M., Diebold, M., Szewczyk, M. M., Baršytė-Lovejoy, D., Arrowsmith, C. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.12.439490 · Cited by 6
Targeting KRASG12C Mutation: Development of effective strategies to overcome drug resistance and limited efficacy
Li, R., Huang, X., Wang, R., Ren, Z., Zhu, Y. L., Lu, T., Sun, Y., & Hao, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117718 · Cited by 6
Multiple functions of BRD4 in maintaining genomic stability in cancers
Huang, Z., Chu, T., & Ma, W. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152393 · Cited by 5
Molecular recognition and effects of a benzothiazole derivative targeting the MYC G-quadruplex
Ni, X., Hu, X.-D., Long, W., Lan, W.-X., Wang, C., Wong, W.-L., & Cao, C.-Y. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf888 · Cited by 4
Overcoming Chemotherapy Resistance in Triple-Negative Breast Cancer with Nanocarrier-Delivered siRNA Therapeutics
Crintea, A., Bocșan, I. C., Jianu, M. E., Şovrea, A. S., Munteanu, C., Kubelac, P. M., Craciun, A. M., & Silaghi, C. N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062311 · Cited by 5
Bicyclic Peptide Library Screening for the Identification of Gαi Protein Modulators
Pepanian, A., Binbay, F. A., Roy, S., Nubbemeyer, B., Koley, A., Rhodes, C. A., Ammer, H., Pei, D., Ghosh, P., & Imhof, D. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00873 · Cited by 5
Development of a Small Molecule Downmodulator for the Transcription Factor Brachyury
Chase, D. H., Bebenek, A. M., Nie, P., Jaime‐Figueroa, S., Butrin, A., Castro, D. A., Hines, J. F., Linhares, B. M., & Crews, C. M. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202316496 · Cited by 5
Classifying covalent protein binders by their targeted binding site
Bedewy, W. A., Mulawka, J. W., & Adler, M. J. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.130067 · Cited by 5
Temporal myc dynamics permit mitotic bypass, promoting polyploid phenotypes
Loycano, M. A., Pienta, K. J., & Amend, S. R. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217526 · Cited by 6
Structure-based artificial intelligence-aided design of MYC-targeting degradation drugs for cancer therapy
Liu, D., Jiang, Y., Ma, B., & Li, L. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151870 · Cited by 6
Recent advance of KRAS-G12C inhibitors for cancer therapy
Li, M., Wang, H., Wang, F., Liu, D., Feng, C. L., Yan, G., & Fan, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117878 · Cited by 6
A Carbohydrate‐based Synthetic Approach to Diverse Structurally and Stereochemically Complex Chiral Polyheterocycles
Bhuyan, S., Das, D., Chakraborty, A., Mandal, S., Dhanabal, K., & Roy, B. (2021) · Chemistry - An Asian Journal · doi:10.1002/asia.202101123 · Cited by 5
4′‐C‐Aminoethoxy‐Modified DNAs Exhibit Increased Nuclease Resistance, Sustained RNase H Activity, and Inhibition of KRAS Gene Expression
Katsuzaki, Y., Tsukimura, R., Chandela, A., Chano, T., & Ueno, Y. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200125 · Cited by 5
Targeting positive cofactor 4 induces autophagic cell death in MYC-expressing diffuse large B-cell lymphoma
Ma, L., Gong, Q., Chen, Y., Luo, P., Chen, J., & Shi, C. (2023) · Experimental Hematology · doi:10.1016/j.exphem.2023.01.001 · Cited by 5
Kinases Controlling Stability of the Oncogenic MYCN Protein
Smith, N., Reznik, E., Bisikirska, B. C., Polychronidou, V., Wang, Q., Zask, A., Forouhar, F., Califano, A., & Stockwell, B. R. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00274 · Cited by 5
Development of Acridone Derivatives: Targeting c-MYC Transcription in Triple-Negative Breast Cancer with Inhibitory Potential
Liang, J., Gao, Z., Yang, L.-L., Zhang, W., Chen, M., & Meng, F. (2023) · Antioxidants · doi:10.3390/antiox13010011 · Cited by 5
Peptidylprolyl Isomerases as In Vivo Carriers for Drugs That Target Various Intracellular Entities
Gałat, A. (2017) · Biomolecules · doi:10.3390/biom7040072 · Cited by 5
MNT Optimization for Intracellular Delivery of Antibody Fragments
Ulasov, A. V., Khramtsov, Y. V., Lupanova, T. N., Tsvetkova, A. D., Rosenkranz, A. A., Slastnikova, T. A., Georgiev, G. P., & Sobolev, A. S. (2018) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672918020023 · Cited by 5
Where and How in the mTOR Pathway Inhibitors Fight Aging: Rapamycin, Resveratrol, and Metformin
Arbor, S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79338 · Cited by 5
Structure and function of Pygo in organ development dependent and independent Wnt signalling
Shi, Y., Wu, X., Zhu, S., Huang, H., Zhuang, J., Yuan, H., Yuan, W., & Zhu, P. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200393 · Cited by 5
Cell detachment ratio on pH-responsive chitosan: A useful biometric for prognostic judgment and drug efficacy assessment in oncology
Yen, C., Young, T., & Huang, T. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.117911 · Cited by 5
Her-2-directed systemic delivery of fatty acid synthase (FASN) siRNA with novel liposomal carrier systems in the breast cancer mouse model
Khan, A., Aljarbou, A. N., Khan, S., & Khan, M. A. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2038613 · Cited by 5
Advances in applications of activity-based chemical probes in the characterization of amino acid reactivities
Li, J., Wang, G., Ye, M., & Qin, H. (2023) · Chinese Journal of Chromatography · doi:10.3724/sp.j.1123.2022.05013 · Cited by 5
Breaking the Fourth Wall: Modulating Quaternary Associations for Protein Regulation and Drug Discovery
Long, M. J. C., Hnedzko, D., Kim, B. K., & Aye, Y. (2018) · ChemBioChem · doi:10.1002/cbic.201800716 · Cited by 5
Development of cell‐based high throughput luminescence assay for drug discovery in inhibiting OCT4/DNA‐PKcs and OCT4–MK2 interactions
Mohiuddin, I. S., Wei, S., Yang, I., Martinez, G. M., Yang, S., Cho, E. J., Dalby, K. N., & Kang, M. H. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27712 · Cited by 5
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs)Preprint
Zhang, L., Deng, T., Liufu, Z., Liu, X., Chen, B., Hu, Z., Liu, C., Tracy, M. E., Lu, X., Wen, H., et al. (2024) · eLife · doi:10.7554/elife.99340 · Cited by 5
The rise of AlphaFold in drug design
Stecuła, A., Paul, R., Litchfield, K., Dalton, S. E., Low, C. M. R., Reis, C. R., & Congreve, M. (2025) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2025.09.002 · Cited by 4
BioLLMNet: enhancing RNA-interaction prediction with a specialized cross-LLM transformation network
Abir, A. R., Tahmid, M. T., & Bayzid, M. S. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf549 · Cited by 4
A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation
Balakumar, P., Mulukuri, N. V. L. S., & Jagadeesh, G. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108945 · Cited by 5
Discovery of de novo peptides by mRNA and RaPID displays with post-translational modification methods
Zhang, Y., & Suga, H. (2026) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2026.103477 · Cited by 4
From undruggable to degradable: Strategic expansion of targeted protein degradation in cancer therapy
Sung, J., Seo, Y., & Lee, J.-Y. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.031 · Cited by 4
Distal Covalent Targeting Suppresses Signaling of Oncogenic K-Ras(G13C) in Cancer Cells
Zheng, Q., Shen, T., Pampel, J., & Shokat, K. M. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00249 · Cited by 4
Self-citation
Role of MYC inhibition in overcoming resistance to HER2-targeted therapies for breast cancer
Tanwisa, T., Raj, A., Puttiga, A., Gopinathan, A., & Alex, A. T. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123902 · Cited by 5
CD5+MYC+ predicts worse prognosis in diffuse large B-cell lymphoma
Lu, T., Wu, S., Zhou, X., Zhang, Y., Hong, T., Cai, D., Hua, H.-Y., Qi, X., & Wu, X. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104326 · Cited by 4
El cáncer de pulmón de células no pequeñas en la era de la medicina de precisión
Rivas, S., & Armisén, R. (2022) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2022.01.001 · Cited by 4
General Strategies for Rational Design and Discovery of Multitarget Drugs
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_18 · Cited by 4
mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death
Leibowitz, B. J., Zhao, G., Xia, W., Wang, Y., Ruan, H., Zhang, L., & Yu, J. (2023) · Oncogene · doi:10.1038/s41388-023-02706-6 · Cited by 4
Targeting the Plasmodium falciparum UCHL3 ubiquitin hydrolase using chemically constrained peptides
King, H. R., Bycroft, M., Nguyen, T., Kelly, G. P., Vinogradov, A. A., Rowling, P. J. E., Stott, K. M., Ascher, D. B., Suga, H., Itzhaki, L. S., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322923121 · Cited by 4
The RAS Signaling Network and Cancer
Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4
Microarrays and NGS for Drug Discovery
Pop, L., Zănoagă, O., Chiroi, P. A., Nutu, A. M., Korban, S. S., Stefan, D. C., Irimie, A., & Berindan‐Neagoe, I. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96657 · Cited by 4
MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis
Nguyen, H. V., Vandenberg, C. J., Robati, M., Ng, A. P., & Cory, S. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01119-y · Cited by 5
Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin
Yin, S.-S., Chen, C., Liu, Z., Liu, S., Guo, J., Zhang, C., Zhang, Q.-W., & Gao, F. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2209963 · Cited by 4
Systematic Targeting of Protein Complexes with Molecular COUPLrs
Yang, D., Harry, S. A., Chong, H. B., Khandelwal, N., Zhang, E., Nordenfelt, N. S., Chen, N. J., Lee, C., Kaluziak, S. T., Codd, E. M., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-2314 · Cited by 4
Cell Proliferation Is Strongly Associated with the Treatment Conditions of an ER Stress Inducer New Anti-Melanoma Drug in Melanoma Cell Lines
Szász, I., Koroknai, V., Patel, V., Hajdú, T., Kiss, T., Ádány, R., & Balázs, M. (2021) · Biomedicines · doi:10.3390/biomedicines9020096 · Cited by 4
Sequence‐Selective Covalent CaaX‐Box Receptors Prevent Farnesylation of Oncogenic Ras Proteins and Impact MAPK/PI3 K Signaling
Franz, M., Mörchen, B., Degenhart, C., Gülden, D., Shkura, O., Wolters, D. A., Koch, U., Klebl, B., Stoll, R., Helfrich, I., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100167 · Cited by 4
The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme
Urban‐Wójciuk, Z., Graham, A., Barker, K. T., Kwok, C., Sbirkov, Y., Howell, L., Campbell, J., Woster, P. M., Poon, E., Petrie, K. R., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00386-6 · Cited by 4
Significance of Selective Protein Degradation in the Development of Novel Targeted Drugs and Its Implications in Cancer Therapy
Yang, J., Wang, Q.-L., Feng, G., & Zeng, M. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900210 · Cited by 4
Phytochemical Regulation of RNA in Treating Inflammatory Bowel Disease and Colon Cancer: Inspirations from Cell and Animal Studies
Zhang, G., Zhang, C., Sun, J., Xiong, Y., Wang, L., & Chen, D. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000354 · Cited by 4
Epigenetic inactivation of oncogenic brachyury (TBXT) by H3K27 histone demethylase controls chordoma cell survivalPreprint
Cottone, L., Hookway, E. S., Cribbs, A. P., Wells, G., Lombard, P., Ligammari, L., Tumber, A., Tirabosco, R., Amary, F. M., Szommer, T., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/432005 · Cited by 4
Enhancing c-MYC degradation via 20S proteasome activation induces in vivo anti-tumor efficacyPreprint
Njomen, E., Lansdell, T. A., Vanecek, A. S., Benham, V., Bernard, M. P., Yang, Y.-T., Schall, P. Z., Isaac, D., Alkharabsheh, O. A., Al-Janadi, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.24.265470 · Cited by 4
Systematic silencing of oncogenic fusion transcripts with ultra-precise CRISPR-Cas13bPreprint
Hu, W., Chen, H., Casan, J. M. L., Shembrey, C., He, S., Brown, L. M., Hughes, T. P., White, D. L., de Weck, A., Voskoboinik, I., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.10.637348 · Cited by 4
Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors
Hylton-McComas, H. M., Cordes, A. F., Floros, K. V., Faber, A. C., Drapkin, B. J., & Miles, W. O. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189332 · Cited by 3
Pharmacologic inhibition of BMI1 exerts antitumor effects against MYCN-amplified neuroblastoma, with activation of the p53 pathway
Hirayama, M., Yamada, E., Aoki, H., Izumi, K., Amano, A., Toriuchi, K., Ogami, K., Nagasaka, M., Inoue, Y., Hayashi, H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-06922-w · Cited by 3
Targeting oncogenic K-RAS mutants with small-molecule degrader XMU-MP-9 through NEDD4-1
Zeng, T., Jiang, T., Zhang, B., Zhang, T., Dai, W., Yin, X., Li, Y., Yu, Z., Wu, C., Wu, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.031 · Cited by 4
Natural lignan justicidin A-induced mitophagy as a targetable niche in bladder cancer
Chang, K.-H., Chen, H., Chen, C.-Y., Tsai, S.-P., Hsu, M.-Y., Wang, P.-Y., Wu, S., & Su, C. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111723 · Cited by 3
Chromatin remodeling complexes: architects influencing breast cancer progression
Giovani, O., Eckersley, G. S., Jones, H. R., & Nagarajan, S. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1690350 · Cited by 3
Targeting the Spliceosomal Protein USP39 Through Allosteric Ligands and PROTAC‐Induced Degradation
Schäfer, D., Prieto‐Garcia, C., Wang, J., Heinz, M., Matković, V., Kielkowski, P., Hasselbeck, S., Shah, V. J., Knapp, S., Hummer, G., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202516809 · Cited by 3
Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets
Hu, Z., Sha, Z., Martı́, J., Guo, S., & Tao, S. (2026) · JACS Au · doi:10.1021/jacsau.5c01097 · Cited by 3
Fusion Strategy of DNA-Encoded Libraries Drives Discovery of Allosteric Inhibitors of SARS-CoV-2 RdRp
Li, L., Wang, X., Ding, P., Shen, X., Hu, H., Wang, X., Jin, R., Wu, X., Zhang, Y. S., Lu, W., et al. (2026) · JACS Au · doi:10.1021/jacsau.5c01698 · Cited by 4
Computational advances in RNA-small molecule binding site prediction
Yang, L., Zou, Y., Liu, Y., & Feng, Y. (2026) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2026.02.003 · Cited by 3
Fulfilling multiple roles in PROTAC design: The emerging potential of oligonucleotides
Rodrigues, D. A., Pires, G. S., Roy, U., Conway, E., & Pinheiro, P. D. S. M. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118688 · Cited by 3
Condensate protein aggregation in ALS/FTD is regulated by GGGGCC-repeat RNA scaffolds
Liu, Y., Song, M., Wan, L., Guo, P., & Han, D. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01785-9 · Cited by 4
Black-box data: a new paradigm for biomedicine in the AI era
Naef, L., & Bronstein, M. M. (2026) · Chemical Science · doi:10.1039/d6sc01189f · Cited by 4
Hallmarks and correlates of effective adoptive cell immunotherapy for cancer
Krishna, S., Robbins, P. F., Lowery, F. J., & Rosenberg, S. A. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01312-3 · Cited by 4
The emerging role of proteolysis targeting chimeras (PROTACs) in the treatment of Alzheimer’s disease
George, N., Akhtar, M. J., Balushi, K. A. A., Safi, S. Z., Azmi, S. N. H., & Khan, S. A. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03026-w · Cited by 3
Insulin‐like Growth Factor 2‐Tagged Aptamer Chimeras (ITACs) Modular Assembly for Targeted and Efficient Degradation of Two Membrane Proteins
Tian, Y., Miao, Y., Guo, P., Wang, J., & Han, D. (2023) · Angewandte Chemie · doi:10.1002/ange.202316089 · Cited by 3
Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience
Rekowska, A. K., Rola, P., Kwiatkowska, A., Wójcik-Superczyńska, M., Gil, M., Krawczyk, P. A., & Milanowski, J. (2024) · Biomedicines · doi:10.3390/biomedicines12020325 · Cited by 3
Design of lipid-based formulations for oral delivery of a BASP1 peptide targeting MYC-dependent gastrointestinal cancer cells
To, D., Steinbring, C., Weber, L. I., Ricci, F., Polidori, I., Postina, A., Hartl, M., & Bernkop‐Schnürch, A. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113677 · Cited by 3
A Ligase‐Based Two‐Step Approach for the Generation of Bicyclic Peptides Containing a Benzylphenyl Thioether Framework
Zhang, H., Wei, H., Xue, J., Xia, Z., Zheng, F., Wan, X., Li, Z., & Fang, G. (2025) · ChemBioChem · doi:10.1002/cbic.202500240 · Cited by 3
Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas
Zheng, Q., Wang, T., Zou, Z., Ma, W., Dong, Z., Zhong, J., Liu, W., Xu, Y., Hu, T., Sun, W. D., et al. (2025) · Biomolecules · doi:10.3390/biom15060904 · Cited by 3
KRAS-induced STN1 (OBFC1) promotes proper CTC1–STN1–TEN1 complex-independent DNA double-strand break repair and cell cycle checkpoint maintenance in pancreatic cancer
Shen, C., Cui, T., Yang, L., Gui, L., Corrales-Guerrero, S., Nair, S., Li, H., Karasinska, J. M., Topham, J. T., Renouf, D. J., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf983 · Cited by 3
Nanostructures for Externally Triggered Chemo/Thermal Therapies
Parchur, A. K., Jagtap, J. M. M., Sharma, G., Gogineni, V. R., Hansen, C. P., White, S. B., & Joshi, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813906-6.00006-8 · Cited by 4
Quantitative and multiplexed chemical-genetic phenotyping in mammalian cells with QMAP-Seq
Brockway, S., Wang, G., Jackson, J. M., Amici, D. R., Takagishi, S. R., Clutter, M. R., Bartom, E. T., & Mendillo, M. L. (2020) · Nature Communications · doi:10.1038/s41467-020-19553-8 · Cited by 3
Preclinical Studies of PROTACs in Hematological Malignancies
Fuchs, O., & Bokorová, R. (2021) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x21666210308111546 · Cited by 3
Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance
Rytlewski, J. D., Brockman, Q. R., Dodd, R. D., Milhem, M. M., & Monga, V. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.88 · Cited by 3
Polypharmacology in Drug Design and Discovery—Basis for Rational Design of Multitarget Drugs
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_12 · Cited by 3
The polymethoxylated flavone hexamethylquercetagetin suppresses NF-κB signaling and inhibits cell survival in cervical carcinoma
Sun, Y., Li, N., Cai, Y., Zhao, X., & Yang, H. (2022) · Growth Factors · doi:10.1080/08977194.2022.2144282 · Cited by 3
Design, synthesis, and activity evaluation of 2-iminobenzimidazoles as c-Myc inhibitors for treating multiple myeloma
Li, S., Wang, Y., Yin, J., Li, K., Liu, L., & Gao, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28411 · Cited by 3
Mechanisms of Cbl-Mediated Ubiquitination of Proteins in T and Natural Killer Cells and Effects on Immune Cell Functions
Nath, P. R., & Isakov, N. (2024) · Life · doi:10.3390/life14121592 · Cited by 3
Therapeutic approaches targeting oncogenic proteins in myeloid leukemia: challenges and perspectives
Yan, X. Y., Kang, Y. Y., Zhang, Z. Y., Huang, P. C., Yang, C., & Naranmandura, H. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2443577 · Cited by 3
Characterization of cancer-driving nucleotides (CDNs) across genes, cancer types, and patients
Zhang, L., Deng, T., Liufu, Z., Chen, X., Wu, S., Liu, X., Shi, C., Chen, B., Hu, Z., Cai, Q., et al. (2024) · eLife · doi:10.7554/elife.99341.3 · Cited by 3
Sex, life, and death in MYC-driven lymphomagenesis
Dang, C. V. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.009 · Cited by 3
Self-citation
An integrated model for predicting KRAS dependency
(2023) · doi:10.1371/journal.pcbi.1011095 · Cited by 3
Facile Synthesis of Homodimeric Protein Ligands
Gui, W., & Kodadek, T. J. (2023) · ChemBioChem · doi:10.1002/cbic.202300392 · Cited by 3
Targeting RNA with Small Molecules
Zhang, P., Bush, J. A., Childs‐Disney, J. L., & Disney, M. D. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_96 · Cited by 3
Reduced expression of dMyc mitigates TauV337M mediated neurotoxicity by preventing the Tau hyperphosphorylation and inducing autophagy in Drosophila.
Pragati, Chanu, S., & Sarkar, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134622 · Cited by 3
SHP2 Inhibition Abrogates MEK inhibitor Resistance in Multiple Cancer ModelsPreprint
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Araki, K. Y., Simeone, D. M., Miller, G., Neel, B. G., & Tang, K. H. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/307876 · Cited by 3
Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusionsPreprint
Hu, W., Kumar, A., Qi, S., Sadras, T., Casan, J. M. L., Ma, D. K. G., Brown, L. M., Haber, M., Voskoboinik, I., Trapani, J. A., et al. (2022) · Research Square · doi:10.1101/2022.06.22.497105 · Cited by 2
Pharmacotherapy Approach of Peptide‐Assisted Nanoparticle
Kumar, S. A., Das, R. R., & Malik, S. (2024) · Wiley eBooks · doi:10.1002/9781119900931.ch15 · Cited by 3
Nanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradationPreprint
Ghosal, S., Robertus, C. M., Wang, J., Chan, H. W., Alamgir, A., Almonte, J., & Alabi, C. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.17.584721 · Cited by 5
On the discovered Cancer Driving Nucleotides (CDNs) –Distributions across genes, cancer types and patientsPreprint
Zhang, L., Deng, T., Liufu, Z., Chen, X., Wu, S., Liu, X., Shi, C., Chen, B., Hu, Z., Cai, Q., et al. (2024) · eLife · doi:10.7554/elife.99341.1 · Cited by 3
BioLLMNet: Enhancing RNA-Interaction Prediction with a Specialized Cross-LLM Transformation NetworkPreprint
Tahmid, M. T., Abir, A. R., & Bayzid, M. S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.02.616044 · Cited by 3
Context-dependent translation inhibition as a novel oncology therapeutic modalityPreprint
Diamond, P. D., Sauer, P. V., Holm, M., Swanson-Swett, C. J., Ferguson, L., Bratset, N. M., Wienker, G. W., Sim, J. S., Adams, H. K., Kenner, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.09.632223 · Cited by 3
Predicting PROTAC-targeted Degradation and Designing Androgen Receptor Degraders with AiPROTACPreprint
Zhang, L., Sun, R., Li, X., Ren, C., Long, Y., Tan, W., Wang, X., Zou, K., Yang, X., Wu, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.26.640266 · Cited by 5
Structure-Activity Relationship Studies and Design of a Ptpn22 Inhibitor with Enhanced Isozyme Selectivity and Cellular Efficacy
Jassim, B. A., Bai, Y., Qu, Z., Sander, C. J., Lin, J., Miao, J., & Zhang, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117129 · Cited by 2
Liquid Chromatography Combined With Tandem Mass Spectrometry for the Pharmacokinetic and Metabolism Studies of PROTAC ARV‐471 in Rats
Huang, W., Zhang, H., Zhou, Y., Liu, X., Zhang, Q., & Ma, X. (2025) · Biomedical Chromatography · doi:10.1002/bmc.6068 · Cited by 2
Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models
Yu, M., Sample, J. W., Yan, I. K., Takaichi, S., Tomlinson, J. L., Loeuillard, E. J., Watkins, R. D., Werneburg, N. W., Abdelrahman, A. M., Carlson, D. M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001256 · Cited by 2
Allosteric inhibitors for the treatment of cancers (2021-): A review from medicinal chemistry perspectives
Ma, F., Chen, Y., Ni, Y., He, H., Ji, O., Quan, X., & Qi, B. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142985 · Cited by 2
Direct Cellular Screening of Pd-Mediated Arylation of Cyclic Peptide Binders Targeting Ubiquitin Chains: Toward Modulating NEMO Liquid–Liquid Phase Separation
Hasan, M., Vodnala, N., Glagovsky, Y., Saed, Y., Kriegesmann, J., Suga, H., & Brik, A. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c09059 · Cited by 2
On-DNA Binder Confirmation: Increasing Confidence in DEL Hits
Mantell, M. A., Pahil, K. S., Holman, K. R., Alper, J., Jones, C. M., Yao, G., & Marcaurelle, L. A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01885 · Cited by 3

Authors: Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L.
Affiliations: The Wistar Institute (US)
Icahn School of Medicine at Mount Sinai (US)
Howard Hughes Medical Institute (US)
Institució Catalana de Recerca i Estudis Avançats (ES)
Corresponding author: Dang, Chi V.
Reddy, E. Premkumar
Shokat, Kevan M.
Soucek, Laura
ORCID: Dang, Chi V.
Reddy, E. Premkumar
Shokat, Kevan M.
Soucek, Laura
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2017-06-23
Volume: 17
Issue: 8
Pages: 502-508
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc.2017.36
PMC: PMC5945194
OpenAlex: W2692768525
Cited by: 927
References: 57
Citations by year: 2026: 93 · 2025: 113 · 2024: 125 · 2023: 110 · 2022: 121 · 2021: 121 · 2020: 113 · 2019: 63 · 2018: 58 · 2017: 10
FWCI: 6.26
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Cancer Institute (R01CA057341, R01CA158209, R01CA051497)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: oncogenic Ras, MYC oncogene, oncogene targeting, anticancer drug development
MeSH terms: Antineoplastic Agents, Humans, Neoplasms, Receptors, Androgen, Oncogene Proteins, Fusion, Proto-Oncogene Proteins c-myc, NF-kappa B, ras Proteins, Proto-Oncogene Proteins c-myb, Drug Discovery, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drugging the ‘undruggable’ cancer targets

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks